


APRIL 24, 1997

PATENT DEPT.
AMGEN



PTAS

UNITED STATES DEPARTMENT OF COMMERCE
Patent and Trademark Office
ASSISTANT SECRETARY AND COMMISSIONER
OF PATENTS AND TRADEMARKS
Washington, D.C. 20231



100365306A

AMGEN

DANIEL R. CURY
U.S. PATENT OPERATIONS/DRC, DEPT. 431
1840 DEHAVILLAND DRIVE
THOUSAND OAKS, CALIFORNIA 91320-1789

UNITED STATES PATENT AND TRADEMARK OFFICE
NOTICE OF RECORDATION OF ASSIGNMENT DOCUMENT

THE ENCLOSED DOCUMENT HAS BEEN RECORDED BY THE ASSIGNMENT DIVISION OF THE U.S. PATENT AND TRADEMARK OFFICE. A COMPLETE MICROFILM COPY IS AVAILABLE AT THE ASSIGNMENT SEARCH ROOM ON THE REEL AND FRAME NUMBER REFERENCED BELOW.

PLEASE REVIEW ALL INFORMATION CONTAINED ON THIS NOTICE. THE INFORMATION CONTAINED ON THIS RECORDATION NOTICE REFLECTS THE DATA PRESENT IN THE PATENT AND TRADEMARK ASSIGNMENT SYSTEM. IF YOU SHOULD FIND ANY ERRORS OR HAVE QUESTIONS CONCERNING THIS NOTICE, YOU MAY CONTACT THE EMPLOYEE WHOSE NAME APPEARS ON THIS NOTICE AT 703-308-9723. PLEASE SEND REQUEST FOR CORRECTION TO: U.S. PATENT AND TRADEMARK OFFICE, ASSIGNMENT DIVISION, BOX ASSIGNMENTS, NORTH TOWER BUILDING, SUITE 10C35, WASHINGTON, D.C. 20231.

RECORDATION DATE: 02/24/1997

REEL/FRAME: 8371/0136
NUMBER OF PAGES: 6

BRIEF: ASSIGNMENT OF ASSIGNEE'S INTEREST (SEE DOCUMENT FOR DETAILS).

ASSIGNOR:
SYNERGEN, INC.

DOC DATE: 12/31/1994

ASSIGNEE:
AMGEN INC.
1840 DEHAVILLAND DRIVE
THOUSAND OAKS, CALIFORNIA
91320-1789

SERIAL NUMBER: 08453176 50225 US K
PATENT NUMBER:

FILING DATE: 05/30/1995
ISSUE DATE:

SERIAL NUMBER: 08452242 50225 US J
PATENT NUMBER:

FILING DATE: 05/26/1995
ISSUE DATE:

SERIAL NUMBER: 08452229 50225 US I
PATENT NUMBER:

FILING DATE: 05/26/1995
ISSUE DATE:

SERIAL NUMBER: 08451374 50225 US H
PATENT NUMBER:

FILING DATE: 05/26/1995
ISSUE DATE:

SERIAL NUMBER: 08453183 SO-125 US G
PATENT NUMBER:

FILING DATE: 05/30/1995
ISSUE DATE:

SERIAL NUMBER: 08448245 SO-225 US F
PATENT NUMBER:

FILING DATE: 05/23/1995
ISSUE DATE:

SERIAL NUMBER: 08182183 SO-225 US E
PATENT NUMBER:

FILING DATE: 05/23/1994
ISSUE DATE:

SERIAL NUMBER: 08052541 SO-225 US D
PATENT NUMBER:

FILING DATE: 04/20/1993
ISSUE DATE:

SERIAL NUMBER: 07855413 SO-225 USC
PATENT NUMBER:

FILING DATE: 03/19/1992
ISSUE DATE:

SERIAL NUMBER: 07788423 SO-225 USB
PATENT NUMBER:

FILING DATE: 11/06/1991
ISSUE DATE:

SERIAL NUMBER: 07774109 SO-225 USA
PATENT NUMBER:

FILING DATE: 10/08/1991
ISSUE DATE:

SERIAL NUMBER: 07764685 SO-225 US O
PATENT NUMBER:

FILING DATE: 09/20/1991
ISSUE DATE:

SERIAL NUMBER: 08446383 SO-325 US A
PATENT NUMBER:

FILING DATE: 05/22/1995
ISSUE DATE:

SERIAL NUMBER: 08340821 SO-325 US O
PATENT NUMBER:

FILING DATE: 11/15/1994
ISSUE DATE:

DOROTHY RILEY, EXAMINER
ASSIGNMENT DIVISION
OFFICE OF PUBLIC RECORDS

03-04-1997

FEB 24 1997

Revised Form PTO-1595
(Rev. 6-93)

MFD 2-24-97

U.S. Department of Commerce
RECEIVED
U.S. Patent and Trademark Office

100365306

ed original documents or copy thereof.

To the Honorable Commissioner of

1. Name of conveying party:
Synergen, Inc.Additional name(s) of conveying party(ies) attached? Yes No2. Name and address of receiving party(ies):
Name: Amgen Inc.

Internal Address:

Street Address: 1840 DeHavilland Drive

City: Thousand Oaks State: CA Zip: 91320-1789

3. Nature of conveyance:

- Assignment Merger
 Security Agreement Change of Name
 Other _____

Execution Date: December 31, 1994

Additional name(s) & address(es) attached? Yes No

4. Application numbers:

If this document is being filed together with a new application, the execution date of the application is: _____

A. Patent Application Nos.: 08/453,176; 08/452,242;
08/452,229; 08/451,374; 08/453,183; 08/448,245;
08/182,183; 08/052,541; 07/855,413; 07/788,423
07/774,109; 07/764,685; 08/446,383; 08/340,821

B. Patent Nos.

Additional numbers attached? Yes No

5. Name and address of party to whom correspondence concerning document should be mailed:

Name: U.S. Patent Operations/DRC

Internal Address: Dept. 431

Amgen

Street Address: 1840 DeHavilland Drive

City: Thousand Oaks State: CA Zip: 91320-1789

6. Total number of applications and patents involved: 14

7. Total fee (37 CFR 3.41).....\$ 560.00

 Enclosed Authorized to be charged to deposit account.

8. Deposit account number: 01-0519

 The Commissioner is hereby authorized to charge any additional filing fees which may be required or credit any overpayment to Deposit Account No. 01-0519

DO NOT USE THIS SPACE

9. Statement and signature.

To the best of my knowledge and belief, the foregoing information is true and correct and any attached copy is a true copy of the original document

Daniel R. Curry

Name of Person Signing

Signature

February 18, 1997

Date

Total number of pages including cover sheet, attachments, and document: 5

410 JG 01-0519 03/03/97 08433175
41-82 381 560.00CH

CERTIFICATE OF MAILING

I hereby certify that this correspondence is being deposited with the United States Postal Service as first class mail in an envelope addressed to the Box Assignment, Assistant Commissioner for Patents, Washington, D.C. 20231, on the date appearing below.

2/18/97

Date

Freddie Craft
Signature

EXHIBIT A

<u>U.S. Patent Application</u>		
<u>Serial No:</u>	<u>Date Filed</u>	<u>Title</u>
08/453/176	05-30-95	Glial Cell Line-Derived Neurotrophic Factor ("GDNF")
08/452,242	05-26-95	Same
08/452,229	05-26-95	Same
08/451,374	05-26-95	Same
08/453,183	05-30-95	Same
08/448,245	05-23-95	Same
08/182,183	05-23-95	Same
08/052,541	04-20-93	Same
07/855,413	03-19-92	Same
07/788,423	11-06-91	Same
07/774,109	10-08-91	Same
07/764,685	09-20-91	Same
08/446,383	05-22-95	Method for Using GDNF as a Neuroprotective Agent
08/340,821	11-15-94	Same

<u>Foreign Patent Application</u>		
<u>Serial No/Country:</u>	<u>Date Filed</u>	<u>Title</u>
26811/92/AU	09-17-92	Glial Derived Neurotrophic Factor
1053/BS	09-17-92	Same
2119463/CA	09-17-92	Same
92921022.7/EP	09-17-92	Same
941285/FI	09-17-92	Same
P9400717/HU	09-17-92	Same
103223/IE	09-17-92	Same
103223/IL	09-17-92	Same
506234/93/JP	09-17-92	Same
700860/94/KR	09-17-92	Same
925293/MX	09-17-92	Same
9409222/NO	09-17-92	Same
244392/NZ	09-17-92	Same
44956/PH	09-18-92	Same
100879/PT	09-17-92	Same
81108487/TW	09-17-92	Same
US92/07888/PCT	09-17-92	Same
92/7159/ZA	09-17-92	Same
115996/IL	11/12/95	Methods of Using GDNF as a Neuroprotective Agent
IB95/01004/PCT	11/13/95	Same
95/9714/ZA	11/15/95	Same

ASSIGNMENT OF PATENT RIGHTS

This Assignment of Patent Rights (hereafter, "Assignment") is made as of December 31, 1994 by Synergen, Inc., a Delaware corporation, having its principal place of business at c/o Amgen Inc., Amgen Center, 1840 Dehavilland Drive, Thousand Oaks, California 91320 (hereafter, "Synergen") to Amgen Inc., a Delaware corporation, having its principal place of business at Amgen Center, 1840 Dehavilland Drive, Thousand Oaks, California 91320 (hereafter, "Amgen").

RECITALS

1. Synergen is the exclusive owner of all right, title to, and interest in patent applications relating to Glial Cell Line-Derived Neurotrophic Factor pending in the United States Patent and Trademark Office and all foreign counterparts (referred to jointly hereafter as the "Patent Applications"), including those set forth on attached Exhibit A.

2. Synergen has agreed that the Patent Applications are unencumbered and that Synergen has full right and lawful authority to assign and convey the same in the manner set forth herein.

3. Synergen has agreed to transfer and assign all of its right, title to, and interest in the Patent Applications to Amgen.

AGREEMENT

In consideration of the sum of one dollar (\$1.00) and other good and valuable consideration, the receipt of which is hereby acknowledged, Synergen hereby sells, transfers and assigns to Amgen, its successors and assigns the entire right, title and interest in, to and under the Patent Applications, including all priority rights for other countries arising therefrom, all inventions therein disclosed, and any and all Letters Patent of the United States and Patents and of all other countries which may be granted for such inventions, or any of them including divisional, continuation, continuation-in-part, renewal or substitute applications based on the above-identified Patent Applications, any reissue or re-examination of patents and Letters Patent, all such inventions and all rights in such


Patents and Letters Patent to be held and enjoyed by Amgen for its own use and enjoyment to the full end of the term or terms for which such Patents and Letters Patent may be granted.

Synergen further transfers and assigns all claims for damages and/or injunctive relief by reason of past infringement of the Patent Applications and all foreign counterparts thereto, with the right to sue for and collect the same for Amgen's own account and use.

Synergen further transfers and assigns to Amgen the full exclusive benefits of, and all rights, privileges and advantages appertaining to the Patent Applications.

IN WITNESS WHEREOF, the duly authorized representative of Synergen has executed this Assignment as of the date first written above.

Synergen, Inc.

By: 

Name: Robert Attiyeh

Title: Senior Vice President,

Finance & Corporate Development

APOSTILLE

(Convention de La Haye du 5 octobre 1961)

1. Country: United States of America
This public document
2. has been
signed by C. MICHI HASEGAWA
3. acting in the capacity of Notary Public, State of California
4. bears the seal/stamp of C. MICHI HASEGAWA Notary Public,
State of California

CERTIFIED

5. at Sacramento, California
6. the 2ND DAY OF MAY 1996
7. by Deputy Secretary of State, State of California
8. No NP02619
9. Seal/Stamp
10. Signature:

SOS/NP 28 12/95



CALIFORNIA ALL-PURPOSE ACKNOWLEDGMENT

State of California

County of Ventura

On April 23, 1996 before me,

C. Michi Hasegawa


Name and Title of Officer (e.g., "John Doe, Notary Public")

personally appeared Robert S Attyeh

Name(s) of Signer(s)

personally known to me - OR - proved to me on the basis of satisfactory evidence to be the person(s) whose name(s) is/are subscribed to the within instrument and acknowledged to me that he/she/they executed the same in his/her/their authorized capacity(ies), and that by his/her/their signature(s) on the instrument the person(s), or the entity upon behalf of which the person(s) acted, executed the instrument.

WITNESS my hand and official seal.



C. Michi Hasegawa

Signature of Notary Public

OPTIONAL

Though the information below is not required by law, it may prove valuable to persons relying on the document and could prevent fraudulent removal and reattachment of this form to another document.

Description of Attached Document

Title or Type of Document: Assignment of Patent Rights - Synergyn

Document Date: December 31, 1994 Number of Pages: 3

Signer(s) Other Than Named Above: _____

Capacity(ies) Claimed by Signer(s)

Signer's Name: _____

Individual

Corporate Officer

Title(s): SVP - Finance & Corp Dev

Partner — Limited General

Attorney-in-Fact

Trustee

Guardian or Conservator

Other: _____

RIGHT THUMPRINT
OF SIGNER

Top of thumb here

Signer's Name: _____

Individual

Corporate Officer

Title(s): _____

Partner — Limited General

Attorney-in-Fact

Trustee

Guardian or Conservator

Other: _____



RIGHT THUMPRINT
OF SIGNER

Top of thumb here

Signer Is Representing:

Signer Is Representing:
